Samaritan Announces U.S. Patent Allowance Covering PBR Technology.LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX AMEX See: American Stock Exchange :LIV) a developer of innovative drugs to target AIDS, Alzheimer's and Cardiovascular disease, announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has allowed Patent Application entitled "DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. Encoding Peripheral-Type Benzodiazepine benzodiazepine (bĕn'zōdīăz`əpēn'), any of a class of drugs prescribed for their tranquilizing, antianxiety, sedative, and muscle-relaxing effects. Benzodiazepines are also prescribed for epilepsy and alcohol withdrawal. Receptor Associated Protein 7, and Applications or Methods of Use." This United States patent was issued to Georgetown University, research partner and collaborator of Samaritan Pharmaceuticals. Samaritan holds the world-wide exclusive license to this patent and to future issued patents that may be issued in the same patent family. In addition to securing the above patent protection in United States, the Australian Patent Office issued patent number 772764 in August 2004. Samaritan is also seeking patent protection in Canada, Europe, and Japan. "This patent further expands Samaritan's position in the area of PBR PBR Pre-Budget Report PBR Pabst Blue Ribbon PBR Policy Based Routing PBR Payment by Results (UK hospital funding) PBR Permit by Rule PBR Plant Breeder's Rights PBR Performance Based Ratemaking PBR Partition Boot Record proteins," commented Eugene Boyle, CFO See Chief Financial Officer. of Samaritan Pharmaceuticals. Some of the research to date on this patent has been published in the following journals: Li H, Degenhardt, Tobin D, Yao, Z., Tasken K, Papadopoulos V (2001) Identification, localization, and function in steroidogenesis steroidogenesis /ste·roi·do·gen·e·sis/ (ste-roi?do-jen´e-sis) production of steroids, as by the adrenal glands.steroidogen´ic ste·roid·o·gen·e·sis n. The biological synthesis of steroids. of PAP7: A peripheral-type benzodiazepine receptor- and protein kinase A (RI(alpha))-associated protein. Molecular Endocrinology, 15:2211-2228. Liu J, Han Z, Sandrini F, Bei T, Matyakhina L, Stratakis CA, Papadopoulos V (2003) Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor- and PKA pK a /pK a/ the negative logarithm of the ionization constant (K) of an acid, the pH of a solution in which half of the acid molecules are ionized. regulatory subunit type 1A (PRKAR1A PRKAR1A Protein Kinase, Camp-Dependent, Regulatory, Type I, Alpha )-associated protein PAP7 and studies in PRKAR1A mutant cells and tissues. FASEB FASEB Federation of American Societies for Experimental Biology Journal, 17:1189-1191. Full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.02-1066fje Liu J, Cavalli LR, Haddad BR, Papadopoulos V (2003) Molecular cloning, genomic organization, chromosomal mapping and sub cellular localization of mouse PAP7: a PBR and PKA-RI(alpha) associated protein. Gene, 308:1-10. Liu J, Li H, Papadopoulos V (2003) PAP7, a PBR/PKA-RI(alpha)-associated protein: a new element in the relay of the hormonal induction of steroidogenesis. J Steroid Biochemistry & Molecular Biology, 85: 275-283. Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan Pharmaceuticals is a drug development company driven to commercialize innovative drugs. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds, out of its pipeline of 250 possible drug candidates; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion